Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) EPS (Weighted Average and Diluted) (2019 - 2025)

Bioadaptives' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.07 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.07 for Q4 2025, down 75.0% from a year ago — trailing twelve months through Dec 2025 was -$0.11 (down 450.0% YoY), and the annual figure for FY2025 was -$0.15, down 36.36%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.07 at Bioadaptives, down from -$0.04 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.06 in Q2 2024 to a low of -$0.07 in Q4 2025.